Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Arzneimittelforschung

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1055/s-0031-1296295PMID 20648922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunomodulating Effects of OM-89, a Bacterial Extract from Escherichia coli, in Murine and Human Leukocytes

  2009cited by this paper
• Biological activity of bacterial surface components: Bacterial extracts and defined bacterial cell wall components as immunomodulators

  2007cited by this paper
• A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections.

  2005cited by this paper
• Cellular Recognition of Tri-/Di-palmitoylated Peptides Is Independent from a Domain Encompassing the N-terminal Seven Leucine-rich Repeat (LRR)/LRR-like Motifs of TLR2*

  2003cited by this paper
• An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells.

  2002cited by this paper
• Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster.

  2002cited by this paper
• Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains.

  2000cited by this paper
• Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89.

  2000cited by this paper
• Immunostimulatory activity of the bacterial extract OM-8.

  2000influential reference
• Cytokine-Activated Endothelial Cells Delay Neutrophil Apoptosis in Vitro and in Vivo

  1999cited by this paper
• Studies on the immunogenicity of an Escherichia coli extract after oral application in mice.

  1997cited by this paper
• Neutrophil apoptosis is modulated by endothelial transmigration and adhesion molecule engagement.

  1997cited by this paper
• Biological activity of bacterial cell-wall components: immunogenicity of the bacterial extract OM-89.

  1995cited by this paper
• Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial.

  1994cited by this paper
• Oral immunotherapy of recurrent urinary tract infections: a double-blind placebo-controlled multicenter study.

  1993cited by this paper
• Biological activity of bacterial surface components. Immunogenicity and immunomodulatory properties of a bacterial extract from Escherichia coli.

  1991cited by this paper
• Oral immunotherapy in paraplegic patients with chronic urinary tract infections: a double-blind, placebo-controlled trial.

  1990cited by this paper
• Immunobiotherapy with Uro-Vaxom in recurrent urinary tract infection. The German Urinary Tract Infection Study Group.

  1990cited by this paper
• Enhancement of cytokine production and natural killer activity by an Escherichia coli extract.

  1989influential reference
• Activation of natural killer cells and cytokine production in man by bacterial extracts.

  1989cited by this paper
• Induction of tumor cytotoxicity in murine bone marrow-derived macrophages by two synthetic lipopeptide analogues.

  1989cited by this paper
• Enhancement of the humoral immune response and resistance to bacterial infection in mice by the oral administration of a bacterial immunomodulator (OM-89).

  1988cited by this paper
• Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production.

  1988cited by this paper
• Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier.

  1986cited by this paper
• LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP).

  1960cited by this paper

• Therapeutic strategies for uncomplicated cystitis in women

  2024cites this paper
• Evaluation of MV140 in preventing recurrent urinary tract infections: a multicentre double‐blind randomized controlled trial protocol

  2023cites this paper
• Вплив лізату бактерій на морфогенез сперматозоїдів інфертильних чоловіків з хронічним запаленням урогенітального тракту

  2018cites this paper
• Influence of bacterial extract on morphogenesis of spermatozoa of infertile men with chronic inflammation of urogenital tract

  2018cites this paper
• Urinary tract infection of mice to model human disease: Practicalities, implications and limitations

  2015cites this paper
• Способ лечения асимптоматической бактериоспермии

  2014cites this paper
• RECURRENT URINARY TRACT INFECTIONS: CAN IMMUNOACTIVE PROPHYLAXIS IMPROVE DISEASE MANAGEMENT IN HEALTHY WOMEN? Narrative Summary of Selected Presentations given at the OM Pharma/Vifor Pharma URO-VAXOM® Summit, held in Buenos

  2014cites this paper
• Method of treating symptom-free bacteriospermia

  2014cites this paper
• Management of Recurrent Cystitis in Women : Role of the Non-Antimicrobial Prophylaxis Summary of Presentations given at OM Pharma Lunch Symposium at the XX FIGO World Congress in Gynecology and Obstetrics , Rome , 9 th October 2012

  2013cites this paper
• Therapeutic Potential of the Human Gastrointestinal Microbiome

  2013cites this paper